Zion Market Research has published a new report titled “Calcium Channel Blocker Market by Drug class (Dihydropyridine and Non-Dihydropyridine) for Hypertension, Angina Pectoris, Pregnancy, Obesity and Other – Global Industry Perspective, Comprehensive Analysis, and Forecast, 2016 – 2022”. According to the report, the global calcium channel blocker market accounted for USD 11.26 billion in 2016 and is expected to reach USD 15.31 billion, growing at a CAGR of around 5.4% between 2017 and 2022.

Calcium channel blockers are the chemical class of antihypertensive drugs used to treat various ill conditions of the heart and blood vessels. For example, CCB is commonly used in the treatment of angina pectoris, hypertension, and Reynaud’s phenomenon. Combination therapy is commonly used in the treatment of high blood pressure or angina pectoris.

Browse the full report at https://www.zionmarketresearch.com/report/calcium-channel-blocker-market

Based on product, calcium channel blocker market is segmented into two types: Dihydropyridine and Non-Dihydropyridine. Dihydropyridine is one of the important groups of calcium channel blocker which held approximately 65%of the overall market in 2016. Dihydropyridineclass is expected to be the largest segment in the market due to growing demand from pharmaceutical industry.Lower cost and easy availability of the products is expected to propel the growth of Dihydropyridinesegment.Dihydropyridine class of CB market is further sub-segmented into Amlodipine, Cilnidipine, Felodipine, Verapamil, Diltiazem, Isradipine, Nicardipine, Nisoldipine, Nifedipine, and others.Whereas, the Non-Dihydropyridine market is sub-segmented into Diltiazem and Verapamil.

Based on application, calcium channel blocker market segmented into five types: the calcium hypertension, angina pectoris, pregnancy, anti-obesity and other.Hypertension segment the calcium channel blocker market in 2016. For instance, in hypertensionVerapamil and Amlodipine are increasingly used in the pharmaceutical industry. Amlodipine is a first line therapy for the treatment obesity, angina pectoris, and others.

Based on geography, calcium channel blocker market segmented into five major regions: North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.North America accounted for the largest share of the market in terms of consumption.Rising percentage of obese and hypertension patient population in Asia Pacific is expected to prompt the growth of calcium channel blocker market within the forecast period.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global calcium channel blocker which include Pfizer Inc., AstraZeneca Plc., more bay health care LLC., GlaxoSmithKline Plc., Sanofi S.A., Johnson & Johnson, Abcam, able Bioscience, and Clearsynth.